Michigan is currently home to 2175 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of ADRX-0706 in Select Advanced Solid Tumors
Recruiting
The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
Intermittent Hypoxia-initiated Plasticity in Humans: A Multi-pronged Therapeutic Approach to Treat Sleep Apnea and Overlapping Co-morbidities
Recruiting
The prevalence of obstructive sleep apnea (OSA) is high in the United States and is a major health concern. This disorder is linked to numerous heart, blood vessel and nervous system abnormalities, along with increased tiredness while performing exercise likely because of a reduced blood supply to skeletal muscles. The gold standard treatment of OSA with continuous positive airway pressure (CPAP) in many cases does not lead to significant improvements in health outcomes because the recommended n... Read More
Gender:
ALL
Ages:
Between 30 years and 60 years
Trial Updated:
12/13/2024
Locations: John D. Dingell VA Medical Center, Detroit, MI, Detroit, Michigan
Conditions: Obstructive Sleep Apnea
Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS
Recruiting
The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in children with sepsis-induced multiple organ dysfunction syndrome (MODS).
Gender:
ALL
Ages:
Between 1 day and 17 years
Trial Updated:
12/13/2024
Locations: CS Mott Children's Hospital, Ann Arbor, Michigan
Conditions: Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)
Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
Recruiting
This Phase 3 study is an Open Label Extension of the APG-20 Study To Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy
Gender:
ALL
Ages:
13 years and above
Trial Updated:
12/12/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Familial Partial Lipodystrophy
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Recruiting
PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1 immunotherapy agent. Up to one additional systemic anti-cancer therapy for SCLC is allowed, for a total of up to two prior lines of therapy. This study is intended to identify the biomarker-defined subgroup(s) that may benefit most from alisertib treatment and to ev... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: Henry Ford Hospital, Detroit, Michigan
Conditions: Small Cell Lung Cancer
Living Well With Lymphoma
Recruiting
In this study the investigators are proposing to evaluate the efficacy, sustainability, and mechanisms of 3 months of individualized counseling of the FRD delivered by registered dietitians, over 8 sessions by phone/video conferencing on fatigue, quality of life, and associated symptoms in persistently fatigued lymphoma cancer survivors compared to 3 months of individualized counseling of the attention control (matched for time and frequency of interactions with the FRD) the General Health Curri... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Lymphoma
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
Recruiting
The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.
Gender:
ALL
Ages:
Between 13 years and 17 years
Trial Updated:
12/12/2024
Locations: Bloomfield Hills MI, Bloomfield Hills, Michigan
Conditions: Schizophrenia
ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)
Recruiting
ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives. The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatr... Read More
Gender:
ALL
Ages:
Between 14 days and 20 years
Trial Updated:
12/11/2024
Locations: University of Michigan - Mott Children's Hospital, Ann Arbor, Michigan
Conditions: Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Recruiting
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-655, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors. Phase 1 will evaluate the overall safety and tolerability of NVL-655 and will determine the RP2D and, if applicable, the MTD of NVL-655 in patients with advanced ALK+ solid tumors. Phase 2 will determine the objective response rat... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
12/11/2024
Locations: Henry Ford Cancer Institute, Detroit, Michigan
Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
Recruiting
The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response. Each participant will be treated with 8 weeks of a luteinizing hormone-releasing hormone agonist (LHRHa) plus apalutamide (APA) while genome sequence characterization is being done. Participants with biopsy specimens deemed unevaluable for genomic testing will remain on LHRHa plus APA for an additional 16 weeks. Participa... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: University of Michigan Health, Ann Arbor, Michigan
Conditions: Prostate Cancer
Spastic Paraplegia - Centers of Excellence Research Network
Recruiting
The Spastic Paraplegia - Centers of Excellence Research Network (SP-CERN) is a collaborative research consortium dedicated to advancing the understanding, diagnosis, and treatment of hereditary spastic paraplegia (HSP) and primary lateral sclerosis (PLS). Aims of the consortium are to a) perform natural history studies of HSP subtypes, b) discover and validate biomarkers and clinician- and patient-reported outcome measures, c) uncover HSP's molecular pathophysiology and develop rational therapeu... Read More
Gender:
ALL
Ages:
All
Trial Updated:
12/10/2024
Locations: University of Michigan School of Medicine, Ann Arbor, Michigan
Conditions: Hereditary Spastic Paraplegia, Primary Lateral Sclerosis, SPG4, SPG5A, Spastic Paraplegia 4, Spastic Paraplegia 5A, Early Onset Hereditary Spastic Paraplegia, Neuromuscular Diseases, Spastic Paraplegia, Hereditary
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
Recruiting
The primary goal of this Phase I study is to determine the maximum tolerated dose of oncolytic adenovirus mediated double suicide-gene therapy in combination with fractionated stereotactic radiosurgery in patients with recurrent high-grade astrocytoma undergoing resection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme, GBM